Is Sight Sciences, Inc. (SGHT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 20.6% / 30% | 61.4% / 30% | 5.5% / 30% | 4.91% / 5% | ✗ NOT HALAL |
| DJIM | 20.6% / 33% | 61.4% / 33% | 5.5% / 33% | 4.91% / 5% | ✗ NOT HALAL |
| MSCI | 28.3% / 33% | 84.3% / 33% | 7.6% / 33% | 4.91% / 5% | ✗ NOT HALAL |
| S&P | 20.6% / 33% | 61.4% / 33% | 5.5% / 33% | 4.91% / 5% | ✗ NOT HALAL |
| FTSE | 28.3% / 33% | 84.3% / 33% | 7.6% / 50% | 4.91% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 86.2% | |
| Operating Margin | -18.0% | |
| Net Margin | -49.7% | |
| Return on Equity (ROE) | -50.7% | |
| Return on Assets (ROA) | -16.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$30M |
| Free Cash Flow | -$30M |
| Total Debt | $41M |
| Debt-to-Equity | 63.8 |
| Current Ratio | 10.2 |
| Total Assets | $115M |
Price & Trading
| Last Close | $4.00 |
| 50-Day MA | $5.12 |
| 200-Day MA | $5.12 |
| Avg Volume | 328K |
| Beta | 2.4 |
|
52-Week Range
$2.03
| |
About Sight Sciences, Inc. (SGHT)
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sight Sciences, Inc. (SGHT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sight Sciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sight Sciences, Inc.'s debt ratio?
Sight Sciences, Inc.'s debt ratio is 20.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 28.3%.
What are Sight Sciences, Inc.'s key financial metrics?
Sight Sciences, Inc. has a market capitalization of $210M, and revenue of $77M. The company maintains a gross margin of 86.2% and a net margin of -49.7%. Return on equity stands at -50.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.